Posts

New Biotin Formula for Healthier Hair

New Biotin Formula for Healthier Hair

Physician’s Choice Introduces New Biotin Formula for Healthier Hair, Skin, and Nails

After months of development, Physician’s Choice has released an optimized biotin supplement with organic medium chain triglycerides (as goMCT®) to promote glowing hair, luminous skin, and strong nails.

Physician’s Choice, leading brand of science-backed supplements, has revealed an advanced biotin formula containing organic refined coconut oil as goMCT®. This unique biotin supplement delivers essential nutrients to strengthen hair, decrease nail brittleness, and improve skin health while providing extra support and energy from medium chain triglycerides found in coconut oil.

“Coconut oil with biotin has so many great skin and hair benefits,” says Logan Chierotti, who established Physician’s Choice in Westminster, CO. “But what we found is no one is really using coconut oil in their biotin supplements. We saw a need in the marketplace and developed the only biotin currently on the market with organic goMCT®, a refined coconut oil that provides added potency and benefits well beyond regular coconut oil.”

To date, biotin has been a popular supplement for healthier hair, skin, and nails. Evidence has shown that biotin can improve scalp health and hair growth with regular use. One study found significant improvement in hair growth after one month in subjects experiencing hair loss.1 In another study, participants experienced improved nail plate thickness after taking daily biotin supplements.2,3

Physician’s Choice Biotin supplement contains:

10,000 mcg of biotin
150 mg of medium chain triglycerides (as goMCT®)

Coconut oil is made up of triglycerides which are naturally able to penetrate the hair shaft. Compared to other products, coconut oil has been shown to protect hair structure by preventing protein loss in both damaged and undamaged hair. By preventing hair damage, the hair can maintain a healthier appearance.4

Medium-chain triglycerides from coconut oil are especially beneficial for those who want healthier skin and hair while also leading active lifestyles. Researchers at Physician’s Choice point to studies showing that MCT can also increase metabolism and improve endurance for weight management and athletic performance.5

“There is no question that an ever expanding market of biotin supplements is driving demand for higher quality products with proven benefits,” Physician’s Choice spokesman said. Manufactured according to GMP standards, the ingredients in Physician’s Choice Biotin are non-GMO, professional grade, and third-party tested. By implementing natural, potent ingredients, the company is leading the movement for better health.

Physician’s Choice Biotin is available for purchase on Amazon and PhysiciansChoice.com.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

About Physician’s Choice

Physician’s Choice delivers high-quality, physician formulated supplements with clinically tested ingredients to help people across the globe engage in healthier lifestyles with optimal nutritional support and increased athletic performance. Find more resources at PhysiciansChoice.com. Follow their instagram:@physicianschoice, twitter: @PhysiciansCh, and facebook: physicians.choice for further updates and product information.

1 Source: Mukhopadhyay D, Das M, Dhar S, Mukhopadhyay M. Multiple carboxylase deficiency (late onset) due to deficiency of biotinidase. Indian Journal of Dermatology. 2014;59(5):502. doi:10.4103/0019-5154.139910.

2 Source: Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. Cutis. 1993;51(4):303-305. https://www.ncbi.nlm.nih.gov/pubmed/8477615.

3 Source: Colombo VE, Gerber F, Bronhofer M, Floersheim GL. Treatment of brittle fingernails and onychoschizia with biotin: Scanning electron microscopy. Journal of the American Academy of Dermatology. 1990;23(6):1127-1132. doi:10.1016/0190-9622(90)70345-i.

4 Source: Rele AS, Mohile RB. Effect of mineral oil, sunflower oil, and coconut oil on prevention of hair damage. Journal of Cosmetic Science. 2003;54(2):175-192. https://www.ncbi.nlm.nih.gov/pubmed/12715094.

5 Source: Wang Y, Liu Z, Han Y, Xu J, Huang W, Li Z. Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism. PLoS One. 2018;13(2):e0191182. Published 2018 Feb 8. doi:10.1371/journal.pone.0191182

Physician’s Choice Introduces New Biotin Formula for Healthier Hair, Skin, and Nails

Source

Previous Posts

New Biotin Formula for Healthier Hair

New Biotin Formula for Healthier Hair

Physician’s Choice Introduces New Biotin Formula for Healthier Hair, Skin, and Nails

After months of development, Physician’s Choice has released an optimized biotin supplement with organic medium chain triglycerides (as goMCT®) to promote glowing hair, luminous skin, and strong nails.

Physician’s Choice, leading brand of science-backed supplements, has revealed an advanced biotin formula containing organic refined coconut oil as goMCT®. This unique biotin supplement delivers essential nutrients to strengthen hair, decrease nail brittleness, and improve skin health while providing extra support and energy from medium chain triglycerides found in coconut oil.

“Coconut oil with biotin has so many great skin and hair benefits,” says Logan Chierotti, who established Physician’s Choice in Westminster, CO. “But what we found is no one is really using coconut oil in their biotin supplements. We saw a need in the marketplace and developed the only biotin currently on the market with organic goMCT®, a refined coconut oil that provides added potency and benefits well beyond regular coconut oil.”

To date, biotin has been a popular supplement for healthier hair, skin, and nails. Evidence has shown that biotin can improve scalp health and hair growth with regular use. One study found significant improvement in hair growth after one month in subjects experiencing hair loss.1 In another study, participants experienced improved nail plate thickness after taking daily biotin supplements.2,3

Physician’s Choice Biotin supplement contains:

10,000 mcg of biotin
150 mg of medium chain triglycerides (as goMCT®)

Coconut oil is made up of triglycerides which are naturally able to penetrate the hair shaft. Compared to other products, coconut oil has been shown to protect hair structure by preventing protein loss in both damaged and undamaged hair. By preventing hair damage, the hair can maintain a healthier appearance.4

Medium-chain triglycerides from coconut oil are especially beneficial for those who want healthier skin and hair while also leading active lifestyles. Researchers at Physician’s Choice point to studies showing that MCT can also increase metabolism and improve endurance for weight management and athletic performance.5

“There is no question that an ever expanding market of biotin supplements is driving demand for higher quality products with proven benefits,” Physician’s Choice spokesman said. Manufactured according to GMP standards, the ingredients in Physician’s Choice Biotin are non-GMO, professional grade, and third-party tested. By implementing natural, potent ingredients, the company is leading the movement for better health.

Physician’s Choice Biotin is available for purchase on Amazon and PhysiciansChoice.com.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

About Physician’s Choice

Physician’s Choice delivers high-quality, physician formulated supplements with clinically tested ingredients to help people across the globe engage in healthier lifestyles with optimal nutritional support and increased athletic performance. Find more resources at PhysiciansChoice.com. Follow their instagram:@physicianschoice, twitter: @PhysiciansCh, and facebook: physicians.choice for further updates and product information.

1 Source: Mukhopadhyay D, Das M, Dhar S, Mukhopadhyay M. Multiple carboxylase deficiency (late onset) due to deficiency of biotinidase. Indian Journal of Dermatology. 2014;59(5):502. doi:10.4103/0019-5154.139910.

2 Source: Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. Cutis. 1993;51(4):303-305. https://www.ncbi.nlm.nih.gov/pubmed/8477615.

3 Source: Colombo VE, Gerber F, Bronhofer M, Floersheim GL. Treatment of brittle fingernails and onychoschizia with biotin: Scanning electron microscopy. Journal of the American Academy of Dermatology. 1990;23(6):1127-1132. doi:10.1016/0190-9622(90)70345-i.

4 Source: Rele AS, Mohile RB. Effect of mineral oil, sunflower oil, and coconut oil on prevention of hair damage. Journal of Cosmetic Science. 2003;54(2):175-192. https://www.ncbi.nlm.nih.gov/pubmed/12715094.

5 Source: Wang Y, Liu Z, Han Y, Xu J, Huang W, Li Z. Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism. PLoS One. 2018;13(2):e0191182. Published 2018 Feb 8. doi:10.1371/journal.pone.0191182

Physician’s Choice Introduces New Biotin Formula for Healthier Hair, Skin, and Nails

Source

Previous Posts

Aclaris Therapeutics hair loss

Aclaris Therapeutics Patents for Treating Hair Loss Disorders

Aclaris Therapeutics (ACRS) Granted Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders

Aclaris Therapeutics, Inc today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,737,469 and U.S. Patent No. 9,730,877, which are directed to methods related to the use and administration of certain janus kinase (JAK) inhibitors for treating hair loss disorders.

U.S. Patent No. 9,730,877 covers the use of various JAK inhibitors, including tofacitinib, baricitinib, ruxolitinib and decernotinib, to treat androgenetic alopecia, also known as male/female pattern hair loss.

Experienced by 70% of men and 40% of women at some point in their lives, androgenetic alopecia is a genetic disorder and the most common cause of hair loss. The ‘877 Patent contains 22 claims and expires in November 2031.

U.S. Patent No. 9,737,469 covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia.

Additional issued claims pertain to methods of using baricitinib to treat particular phenotypes of alopecia areata, as well as to treat other hair loss disorders. The ‘469 Patent contains 10 claims and expires in November 2031.

These newly allowed patents are owned by The Trustees of Columbia University in the City of New York and exclusively licensed to Aclaris, and are the latest U.S. patents to issue in connection with Aclaris’ JAK drug development program for hair loss disorders.

“We are extremely pleased with the continued development of the patent portfolio we exclusively licensed from Columbia. These new issuances continue to expand the breadth and depth of our JAK inhibitor intellectual property portfolio covering methods of use for certain JAK inhibitors for the treatment of hair loss disorders.

The issuance of these patents is another successful step in the development of a robust patent portfolio relating to JAK inhibition and hair loss,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

Aclaris has exclusively licensed several patents and patent applications involving novel selective JAK 1/3 inhibitors, including a patent portfolio from Rigel Pharmaceuticals, Inc. that covers Aclaris’ product candidates ATI-50001 and ATI-50002, which are oral and topical formulations, respectively, also being developed as potential treatments for alopecia areata.

Additionally, Aclaris has exclusively licensed a patent portfolio from Columbia University directed to methods of using JAK inhibitors for the treatment of alopecia areata, androgenetic alopecia, and other dermatological conditions.

This portfolio includes the recently issued U.S. patents discussed above, as well as an issued U.S. patent directed to methods of treating alopecia areata, androgenetic alopecia and other hair loss disorders by administering ruxolitinib and issued patent claims in Japan directed to pharmaceutical compositions comprising ruxolitinib, baricitinib or other JAK inhibitors for use in treating alopecia areata, androgenetic alopecia and other hair loss disorders.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.

Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the development of Aclaris’ product candidates focused on JAK inhibition for the treatment of hair loss disorders, including Aclaris’ intellectual property strategy. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2016, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, and other filings Aclaris makes with the SEC from time to time.

These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.